J Inherit Metab Dis (2013) 36:159–160
DOI 10.1007/s10545-012-9554-2

ERRATUM

Erratum to: Relationship between enzyme properties and disease progression in Canavan disease

Stephen Zano · Yasanandana S. Wijayasinghe · Radhika Malik · Joshua Smith · Ronald E. Viola

Published online: 9 November 2012

Erratum to: **J Inherit Metab Dis**
DOI 10.1007/s10545-012-9520-z

In the published original article, Table 1, the header "Specific activity" is not given correct. "(U/mg)" should be placed above the left column, "% of native" should be placed above the right column.

The correct table is given here.

The online version of the original article can be found at http://dx.doi.org/10.1007/s10545-012-9520-z.

S. Zano · Y. S. Wijayasinghe · R. Malik · J. Smith · R. E. Viola (✉)
Department of Chemistry, University of Toledo,
Toledo, OH 43606, USA
e-mail: ron.viola@utoledo.edu

Present Address:
R. Malik
Department of Structural and Chemical Biology,
Mount Sinai School of Medicine,
New York, NY 10029, USA

Table 1 Biochemical properties of aspartoacylase clinical mutants

Aspartoacylase mutant	Disease phenotype	Specific activity [a]		Thermal stability (°C)	Conformational stability (mM)
		(U/mg)	% of native		
Native	–	7.5	100 %	59.9	1,150
Mild disease phenotype					
G274R	mild with K213E [b]	2.6	35 %	58.3	**650**
P181T	mild with E285A [b]	2.4	32 %	58.3	**600**
Y231C	mild	1.8	24 %	**49.6**	1,050
P257R	mild with A305E [b]	1.6	21 %	**50.6**	1,000
I143T	mild	1.2	16 %	**51.9**	1,000
K213E	mild with G274R [b]	1.16	15 %	58	**750**
R71H	mild	0.83	11 %	57.2	**650**
Y288C	mild	0.29	4 %	56.7	***250***
	mild with F295S & A305E [b]				
Variable/undetermined disease phenotype					
D249V	variable [c]	2.2	29 %	58.6	**720**
N121I	undetermined [d]	1.2	16 %	**47.1**	**500**
A305E	variable [c] mild with P257R & Y288C [b]	0.78	10 %	58.9	900
F295S	variable [c] mild with Y288C [b]	0.75	10 %	56.6	1,050
E285A	variable [c]	0.02	0.3 %	**48.5**	***125***
Severe disease phenotype					
I143F	severe	0.08	1 %	**51.2**	**600**
C152W	severe	0.07	1 %	58.5	1,100
C152R	severe	0.04	0.5 %	**51.2**	***300***

[a] standard errors on the specific activity measurements are ±5 %

[b] compound heterozygote patients

[c] variable severity and disease progression reported in different patients

[d] reported from a single patient of undetermined phenotype